Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer
Conditions
Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
breast cancer, gemcitabine, lobaplatin, cisplatin
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: lobaplatin Type: Drug
Name: cisplatin Type: Drug
Overall Status
Recruiting
Summary
Gemcitabine plus cisplatin has been proved to be an effective regimen as second-line treatment for metastatic breast cancer patients, especially for those previously treated with anthracyclines and taxanes. Lobaplatin, as the third generation of new cancer drug platinum, has a similar anticancer activity to cisplatin, but less kidney toxicity and gastrointestinal reaction. The purpose of the study is to compare the efficacy and safety of gemcitabine/lobaplatin versus gemcitabine/cisplatin in patients with metastatic breast cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:

- Histologically confirmed metastatic breast cancer

- Disease progression during or after previous 1st line chemotherapy

- Scheduled to receive 2nd line chemotherapy.

- Measurable disease, defined as a least one lesion that can be accurately measured in at least one dimension

- 18 years of age or older

- ECOG performance status of 0-2

- Life expectancy of greater than 6 months

Exclusion Criteria:

- Previous treatment with one of the study drugs

- Application of other cytotoxic chemotherapy or radiotherapy

- Insufficent renal function (creatinine clearance < 60ml/min)

- Clinically unstable brain metastasis

- Pregancy or lactation

- History of other malignancy within last 5 years.
Location
Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Status: Recruiting
Contact: Qingyuan Zhang, MD - 86-451-86298276 - zhma19650210@163.com
Start Date
November 2011
Completion Date
November 2014
Sponsors
Harbin Medical University
Source
Harbin Medical University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page